Attached files
| file | filename |
|---|---|
| EX-10.14 - EXHIBIT 10.14 - SYNERGY PHARMACEUTICALS, INC. | amendmenttotermloanagreeme.htm |
| EX-21 - EXHIBIT 21 - SYNERGY PHARMACEUTICALS, INC. | exhibit21.htm |
| EX-32.2 - EXHIBIT 32.2 - SYNERGY PHARMACEUTICALS, INC. | sgyp-ex322x123117x10k.htm |
| EX-31.1 - EXHIBIT 31.1 - SYNERGY PHARMACEUTICALS, INC. | sgyp-ex311x123117x10k.htm |
| EX-31.2 - EXHIBIT 31.2 - SYNERGY PHARMACEUTICALS, INC. | sgyp-ex312x123117x10k.htm |
| EX-32.1 - EXHIBIT 32.1 - SYNERGY PHARMACEUTICALS, INC. | sgyp-ex321x123117x10k.htm |
| EX-10.13 - EXHIBIT 10.13 - SYNERGY PHARMACEUTICALS, INC. | garyjacobemploymentagreeme.htm |
| 10-K - 10-K - SYNERGY PHARMACEUTICALS, INC. | sgyp-123117x10k.htm |
| EX-10.7 - EXHIBIT 10.7 - SYNERGY PHARMACEUTICALS, INC. | troyhamiltonemploymentagre.htm |
Consent of Independent Registered Public Accounting Firm
Synergy Pharmaceuticals Inc.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statements on Form S3 (No. 333-214013 and 333-177730), Form S-3ASR (No. 333-221501) and Form S-8 (No. 333-193340, 333-205057 and 333-220016) of Synergy Pharmaceuticals Inc. of our reports dated March 1, 2018, relating to the consolidated financial statements, and the effectiveness of Synergy Pharmaceuticals Inc.’s internal control over financial reporting, which appear in this Annual Report on Form 10-K. Our report on the financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
New York, New York
March 1, 2018